• Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

  • info@chv.vc

  • 129 South Street, 4th Floor, Boston, MA 02111

Home / News / Sera Prognostics

Sera Prognostics


Sera Prognostics Announces Pricing of $50 Million Public Offering
  • February 14, 2025
  • -
  • Sera Prognostics
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
  • December 9, 2024
  • -
  • Sera Prognostics
Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution
  • July 1, 2024
  • -
  • Sera Prognostics
Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success
  • December 6, 2023
  • -
  • Sera Prognostics
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
  • May 15, 2023
  • -
  • Sera Prognostics
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
  • February 15, 2023
  • -
  • Sera Prognostics
Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations
  • November 15, 2022
  • -
  • Sera Prognostics
Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members
  • September 22, 2022
  • -
  • Sera Prognostics
Show More

Let’s Connect.

Contact Us
https://chv.vc/wp-content/uploads/2020/08/footer-logo.png

Sitemap

  • Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

About

Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs.

Contact

  • info@chv.vc

Boston Web Design by GoingClear